Psychosocial Supports in Medication-Assisted Treatment: Recent Evidence and Current Practice
Westat
Printer Friendly Version in PDF Format (63 PDF pages)
Psychosocial Supports in Medication-Assisted Treatment: Recent Evidence and Current Practice
ABSTRACT
This report was included as Appendix B of "Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions." That report's purpose was to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
MATPsychLR.pdf
PDF 
Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions
Westat
Printer Friendly Version in PDF Format (47 PDF pages)
ABSTRACT
The purpose of this report is to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions
The purpose of this report is to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
MATPsych.pdf
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
Westat
Printer Friendly Version in PDF Format (3 PDF pages)
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
As the opioid epidemic has evolved into a national crisis, the need for treatment has increased greatly. Medication-assisted treatment (MAT) is a “whole-patient” approach to the treatment of opioid use disorder (OUD) that combines the use of medications and psychosocial supports, such as therapy, counseling, self-help groups, and case manageme
OptimalIB.pdf
Primary and Behavioral Health Care Integration Program: Impacts on Health Care Utilization, Cost, and Quality
Joshua Breslau, Mark J. Sorbero, Daniela Kusuke, Hao Yu, Deborah M. Scharf, Nicole Schmidt Hackbarth, and Harold Alan Pincus
RAND Corporation
Printer Friendly Version in PDF Format (66 PDF pages)
Primary and Behavioral Health Care Integration Program: Impacts on Health Care Utilization, Cost, and Quality
This report describes an extension of the RAND Corporation's evaluation of the Substance Abuse and Mental Health Services Administration's Primary and Behavioral Health Care Integration (PBHCI) grants program. PBHCI grants are designed to improve the overall wellness and physical health (PH) status of people with serious mental illness (SMI) or co
PBHCIP.pdf
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX F: National Drug Codes Used to Identify Prescription Drug Fills for Substance Use Disorders in Preliminary Analysis
National Drug Code
Product Name
Use
Dosage in MG
00456-3330-01
CAMPRAL
AUD
333
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX E: Supplemental Regression Analyses Results
Annual Descriptive Trends and Simple Regression Analysis
We produced annual outcome trends for the average and 95thpercentile for all service categories, comparing non-BH, MH, and SUD diagnosis groups as well as OUD and non-OUD SUD trends. We then produced plotted graphs to visually assess whether there were distinct patterns in results or disco
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX D: Prescription Drug National Drug Codes Used to Identify Opioid Use Disorder Subpopulation
NDC
Prod_Name
Route of Admin
Master Form Code
Strength in MG
Generic Name
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX C: Mental Health and Substance Use Disorder Diagnosis Codes
ICD-9-CM Diagnosis Code
Description of ICD-9-CM Diagnosis Code
MH or SUD Diagnosis Group
Related CCS Category
3090
Adjustment disorder with depressed mood
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX B: Methods
Introduction
The purpose of this appendix is to provide additional details on the methodology and analytic approach used in the study to obtain the results presented in the main section of the report. This includes details on specific codes used in data from the MarketScan CCAE Database, such as International Classification of Diseases, Ninth Re
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. APPENDIX A: Definitions of Acronyms and Abbreviations
Acronym
Definition
ASAM
American Society of Addiction Medicine
ASPE
HHS Office of the Assistant Secretary for Planning and Evaluation
AUD
Alcohol Use Disorder
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. NOTES
Stuart EA, McGinty EE, Kalb L, et al. Increased service use among children with autism spectrum disorder associated with Mental Health Parity Law. Health Affairs. 2017; 36(2): 337-345.
For more information on the federal rulemaking process refer to: https://www.federalregister.gov/uploads/2011/01/the_rulemaking_process.pdf .
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. 5. CONCLUSIONS
MHPAEA Had a Positive Impact on Utilization of Outpatient Behavioral Health Services at the Mean
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. 4. RESULTS
We divide our results into several sections:
Utilization Outcomes .
Average Insurer and Enrollee Spending Outcomes .
Insurer Reimbursement and Enrollee Out-of-Pocket Outcomes .
Out-of-Network Outcomes .
Outcomes for Service Utilizers at the 95th Percentile and Subpopulations .
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. 3. METHODS
Study Period
Our period of study was from January 2005 through September 2015. We selected these years to have an adequate number of pre-parity and post-parity months for analysis.[ 28 ] Within the full study period, we defined three separate time periods to assess the impact of MHPAEA based on the timeline of MHPAEA's implementation:
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. 2. BACKGROUND
Efforts to ensure that individuals with BH conditions receive insurance benefits that are comparable to those with medical conditions have been unfolding over the course of the past two decades. Two federal parity laws have been passed that directly apply to large group health plans.
Assessing the Impact of Parity in the Large Group Employer-Sponsored Insurance Market: Final Report. 1. INTRODUCTION
The Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) ensures that large group health plans and health insurance issuers offer comparable benefits for mental health (MH) and substance use disorder (SUD) services and medical/surgical services. This legislation builds on prior federal parity legislation
